HIV Envelope Protein gp41
"HIV Envelope Protein gp41" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING.
| Descriptor ID |
D015700
|
| MeSH Number(s) |
D12.776.543.512.500.330 D12.776.964.775.325.164.200 D12.776.964.775.562.500.200 D12.776.964.970.880.325.164.200 D12.776.964.970.880.910.330 D23.050.327.520.330
|
| Concept/Terms |
HIV Envelope Protein gp41- HIV Envelope Protein gp41
- Envelope Protein gp41, HIV
- HTLV-III gp41
- gp41(HIV)
- HIV Transmembrane Protein gp41
- env Protein gp41, HIV
- gp41 Envelope Protein, HIV
|
Below are MeSH descriptors whose meaning is more general than "HIV Envelope Protein gp41".
Below are MeSH descriptors whose meaning is more specific than "HIV Envelope Protein gp41".
This graph shows the total number of publications written about "HIV Envelope Protein gp41" by people in this website by year, and whether "HIV Envelope Protein gp41" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Envelope Protein gp41" by people in Profiles.
-
Klasse PJ, Depetris RS, Pejchal R, Julien JP, Khayat R, Lee JH, Marozsan AJ, Cupo A, Cocco N, Korzun J, Yasmeen A, Ward AB, Wilson IA, Sanders RW, Moore JP. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol. 2013 Sep; 87(17):9873-85.
-
Khayat R, Lee JH, Julien JP, Cupo A, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB. Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol. 2013 Sep; 87(17):9865-72.
-
Sivaraman V, Zhang L, Meissner EG, Jeffrey JL, Su L. The heptad repeat 2 domain is a major determinant for enhanced human immunodeficiency virus type 1 (HIV-1) fusion and pathogenicity of a highly pathogenic HIV-1 Env. J Virol. 2009 Nov; 83(22):11715-25.
-
F?tkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008 Oct 02; 359(14):1442-55.
-
Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, Kuritzkes DR. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006; 11(5):619-23.
-
Comardelle AM, Norris CH, Plymale DR, Gatti PJ, Choi B, Fermin CD, Haislip AM, Tencza SB, Mietzner TA, Montelaro RC, Garry RF. A synthetic peptide corresponding to the carboxy terminus of human immunodeficiency virus type 1 transmembrane glycoprotein induces alterations in the ionic permeability of Xenopus laevis oocytes. AIDS Res Hum Retroviruses. 1997 Nov 20; 13(17):1525-32.